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BACKGROUND: The magnitude of prognostically relevant myocardial 
injury after percutaneous coronary interventions remains poorly 
defined. The Society for Cardiovascular Angiography and Interventions 
(SCAI) proposed marked biomarker elevations to define periprocedural 
myocardial infarction (PMI). These consensus-based thresholds have not 
been validated in the era of high-sensitivity cardiac troponins. We sought 
to assess the prognostic impact of SCAI-defined PMI and explore optimal 
prognostic thresholds of high-sensitivity cardiac troponin T (hs-cTnT) after 
elective percutaneous coronary interventions.
METHODS AND RESULTS: We evaluated patients who underwent 
elective percutaneous coronary interventions at 2 tertiary care 
centers with serial hs-cTnT measurements. PMI was defined as peak 
postprocedural hs-cTnT >70× upper reference limit (URL) in patients with 
nonelevated (≤1× URL) baseline levels; or incremental increase >70× URL 
in patients with elevated baseline levels. The primary outcome was 1-year 
all-cause mortality. Of 8140 patients, 220 (2.7%) died within 1 year. In 
multivariable analyses, patients with SCAI-defined PMI (n=140; 1.7%) had 
a higher risk of 1-year mortality (12.9% versus 2.5%, adjusted hazard 
ratio 4.10, 95% CI 2.51–6.68; P<0.001) as well as cardiac mortality 
(11.4% versus 2.1%, adjusted hazard ratio 4.21, 95% CI 2.50–7.11; 
P<0.001). Based on receiver operating characteristics analysis, the optimal 
prognostic threshold of hs-cTnT was >10×URL, observed in 14.6% of 
patients. This threshold showed lower specificity (85.7% versus 98.4%) 
but higher sensitivity (25.4% versus 8.2%) and better overall performance 
for prediction of 1-year mortality compared with the SCAI-defined cutoff 
value of troponin.
CONCLUSIONS: In patients undergoing elective percutaneous coronary 
interventions, SCAI-defined PMI emerged as an independent, highly 
specific, but insensitive predictor of 1-year mortality. Optimal trade-off 
between sensitivity and specificity was observed at a lower threshold of 
hs-cTnT (10× URL) in this cohort.
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cardiac troponins (cTn) are the gold-standard bio-markers for the diagnosis of acute coronary syn-dromes. In clinical settings characterized by less 
extensive myocardial injury, cTn elevations have been 
associated with adverse clinical prognosis in apparently 
healthy individuals1; patients with chronic stable coro-
nary artery disease (CAD)2; and patients undergoing 
coronary revascularization procedures.3 In the context 
of percutaneous coronary interventions (PCI), the mag-
nitude of postprocedural biomarker elevation reflecting 
clinically relevant myocardial damage remains contro-
versial.4 The Society for Cardiovascular Angiography and 
Interventions (SCAI) proposed a definition of peripro-
cedural myocardial infarction (PMI)5 which, compared 
with previous definitions,6 entails substantially higher 
creatine kinase-myocardial band fraction (CK-MB) or 
cTn levels—presumably corresponding to myocardial 
injury large enough to have clinical consequences. The 
SCAI threshold of CK-MB elevation was based on pre-
vious evidence linking these levels to adverse post-PCI 
outcomes,7 and the prognostic impact of this CK-MB-
based definition was prospectively validated in subse-
quent investigations.8,9 In contrast, because of scarce 
outcomes data with cTn, the cutoff value for cTn 
proposed by SCAI was consensus-based and driven 
by assumptions about bioequivalence between the 2 
biomarkers.5 Although cTn—in particular high-sensi-
tivity cardiac troponin T (hs-cTnT)—has progressively 
replaced CK-MB in clinical practice, the prognostic 
value of the troponin-based definition of PMI according 
to SCAI remains poorly defined.
This study sought to assess the prognostic implica-
tions of the SCAI definition of PMI using hs-cTnT, and 
to explore optimal cutoff values of hs-cTnT for predic-
tion of 1-year mortality in a large population of patients 
undergoing elective PCI. A secondary objective com-
pared the prognostic performance of the SCAI defini-
tion of PMI based on hs-cTnT versus CK-MB.
METHODS
The data, analytic methods, and study materials cannot be 
made available to other researchers for purposes of reproduc-
ing the results or replicating the procedure, given constraints 
in broader sharing of the data.
Patient Population
This study included patients who underwent elective PCI at 
2 institutions: Deutsches Herzzentrum München, Munich, 
Germany (between October 2009 and January 2015) and Bern 
University Hospital, Bern, Switzerland10 (between September 
2010 and June 2014). The indication for PCI, performed in 
de novo lesions or in-stent restenosis within native vessels 
or bypass grafts, was symptomatic stable CAD or silent isch-
emia on functional testing. We excluded patients with acute 
coronary syndromes (STEMI or nonST-elevation acute coro-
nary syndromes); undetermined clinical diagnosis; and those 
in whom serial (preprocedural and postprocedural) hs-cTnT 
measurements were not available. Demographic and clinical 
characteristics, procedural information, in-hospital outcomes 
and 1-year follow-up data were systematically and prospec-
tively collected. The study was approved by the institutional 
ethics committees and all patients provided written informed 
consent for prospective follow-up.
Procedures
PCI was performed in accordance with current practice guide-
lines.11 Unfractionated heparin or bivalirudin was admin-
istered during the procedure. The periprocedural use of 
glycoprotein IIb/IIIa inhibitors was left to the discretion of the 
operator. Dual antiplatelet therapy consisting of aspirin and 
a P2Y12 inhibitor (typically clopidogrel) was initiated before, 
at the time, or immediately after the procedure. Aspirin was 
continued indefinitely, and dual antiplatelet therapy duration 
was typically 12 months (at least 1 month after bare-metal 
stent implantation and at least 6 months after drug-eluting 
stent implantation). Other cardiac medications were left at 
the discretion of treating physicians.
Biochemical Analyses
Levels of hs-cTnT were determined at baseline (usually up 
to 6 hours before the index procedure), in at least 1 sample 
within 6 hours after PCI, and on a daily basis thereafter dur-
ing the hospital stay (usually 48 hours). In case of an increase 
WHAT IS KNOWN
• Myocardial injury occurs frequently after percuta-
neous coronary interventions, but the magnitude 
of prognostically relevant biomarker elevation 
(particularly in the era of high-sensitivity troponin 
assays) is not well established.
• The Society for Cardiovascular Angiography and 
Interventions proposed marked biomarker eleva-
tions to define periprocedural myocardial infarc-
tion; the consensus-based threshold for troponin 
elevation has not been validated.
WHAT THE STUDY ADDS
• In a large, contemporary population of patients 
undergoing elective percutaneous coronary interven-
tion, periprocedural myocardial infarction defined 
by the Society for Cardiovascular Angiography and 
Interventions criteria (troponin elevation >70× upper 
reference limit) was an independent, highly specific, 
but insensitive predictor of mortality within 1 year.
• Using a highly sensitive cardiac troponin T assay, 
a substantially lower threshold (10× upper refer-
ence limit) emerged as the optimal prognostic 
cutoff value and led to a better combination of 
sensitivity and specificity compared with the cutoff 
value proposed by the Society for Cardiovascular 
Angiography and Interventions criteria.
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in postprocedural hs-cTnT or if clinically indicated (eg, in 
the presence of new ischemic symptoms or ECG changes), 
repetitive measurements were obtained to assess peak post-
PCI levels. At both institutions, hs-cTnT was measured using 
the same automated analyzer (cobas e 411 immunoanalyzer 
using fourth-generation Elecsys troponin T assay; Roche 
Diagnostics, Mannheim, Germany). This highly sensitive assay 
has a lower limit of detection of 3 ng/L and a 99th percentile 
reference limit of 14 ng/L in apparently healthy individuals.12 
Preprocedural and peak postprocedural hs-cTnT values were 
used for this analysis.
Patient Follow-Up
Patients were prospectively followed throughout 1 year. 
Follow-up was performed by telephone interview at 1 and 
12 months after PCI. Survival data were obtained from hos-
pital records, telephone contact with relatives, general prac-
titioners, referring cardiologists, municipal civil registries, 
insurance companies, or the registration of address office as 
necessary. For patients who underwent subsequent treatment 
at other institutions, external medical records, discharge let-
ters, and coronary angiography documentation were system-
atically collected and reviewed. Adjudication of events using 
original source documents was performed by medical person-
nel blinded to patient clinical or laboratory data.
Clinical End Points and Study 
Assessments
The primary outcome of this analysis was all-cause death 
within 1 year in patients with versus without PMI, defined 
according to the SCAI criteria of troponin elevation (ie, 
without accounting for ancillary criteria of myocardial isch-
emia). Cardiac mortality was defined according to Academic 
Research Consortium criteria as any death because of an 
immediate cardiac cause, procedure-related mortality, or 
death of unknown cause.13 Major adverse cardiac events were 
defined as the composite of cardiac death or MI. PMI was 
defined according to cTn criteria (accounting for preproce-
dural as well as postprocedural levels)5 as follows: (1) peak 
post-PCI hs-cTnT >70× URL in patients with nonelevated pre-
PCI levels (≤1× URL); or (2) incremental increase in hs-cTnT 
>70× URL in patients with elevated pre-PCI levels (>1× URL). 
To explore whether a different threshold for hs-cTnT might 
perform better compared with the SCAI threshold for pre-
diction of mortality, we assessed baseline-adjusted postpro-
cedural levels of hs-cTnT for all patients in accordance with 
the SCAI algorithm, ie, peak post-PCI levels in patients with 
nonelevated pre-PCI levels or incremental increase of hs-cTnT 
in patients with elevated pre-PCI levels. To directly compare 
the prognostic performance of hs-cTnT versus CK-MB, a sec-
ondary analysis assessed the primary outcome in relation to 
SCAI-defined PMI based on hs-cTnT levels (≥70× URL) versus 
CK-MB levels (≥10× URL).5
Statistical Analyses
Statistical analyses were performed with Stata version 14.2 
(Stata Corp, College Station, TX). Continuous variables 
are summarized as mean±SD or median with interquartile 
ranges, and categorical variables as actual numbers and 
percentages. Baseline and procedural characteristics were 
compared with t test, Kruskal-Wallis and Fisher exact test. 
Lesion-level variables were compared with mixed effects 
regression models adjusting for multiple lesions per patient. 
Predictors of SCAI-defined PMI were assessed using univari-
able and multivariable models including candidate predictors 
that were selected based on clinical importance. One-year 
clinical outcomes were analyzed with Cox proportional haz-
ard models and Kaplan-Meier curves were constructed. We 
applied Cox regressions to mortality and cardiac mortality 
using baseline characteristics as predictors. Covariates show-
ing significant (P<0.05) bivariate association with 1-year 
mortality were used in multivariate models. Adjustment was 
made for the following variables: preprocedural hs-cTnT; 
age; sex; diabetes mellitus; hypertension; body mass index; 
multivessel disease; glomerular filtration rate; left ventricu-
lar ejection fraction; balloon diameter; restenotic lesion; and 
pre-PCI TIMI flow. To define a prognostically optimal cutoff 
of hs-cTnT, the discriminating capacity of different levels of 
baseline-adjusted post-PCI hs-cTnT with respect to 1-year 
mortality was assessed by receiver operating characteristic 
curves (ROC) and quantified by areas under the curve. In 
an ancillary approach, the optimal prognostic cutoff value 
was identified applying the methodology of Contal and 
O’Quigley14 implemented in R (R Foundation for Statistical 
Computing, Vienna, Austria) and the package survMisc. 
The latter method chooses the cut point that maximizes a 
rank-based statistic, thus resulting in the smallest P value, 
when comparing survival between 2 groups defined by the 
cut point, and corrects the P value for multiple tests.13 For 
comparison of the predictive value of the hs-cTnT-based ver-
sus CK-MB-based SCAI cutoff of PMI, respective Cox models 
were compared using Harrell’s c statistic.15 A 2-sided P<0.05 
was considered statistically significant.
RESULTS
Of 8729 consecutive patients who underwent elective 
PCI in the 2 institutions during the respective study 
periods, 8140 patients with available serial hs-cTnT 
measurements were included in this analysis (Figure I 
in the Data Supplement). Postprocedural levels of hs-
cTnT are shown in Figure  1A and 1B. SCAI-defined 
PMI was observed in 140 patients (1.7%). Baseline 
(pre-PCI) levels of hs-cTnT were elevated (>1× URL) in 
39.5% (n=3217) of all patients and in 49.3% (n=69) of 
patients with PMI (Figure 1C).
Baseline Characteristics
Baseline clinical characteristics for the main study 
population are summarized in Table 1, and are shown 
for patients with versus without serial hs-cTnT mea-
surements in Table I in the Data Supplement. Patients 
with versus those without PMI had lower body mass 
index, lower left ventricular ejection fraction, more 
frequently had renal dysfunction, tended to be older 
and more commonly women, and had higher levels 
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of preprocedural hs-cTnT. Patients with PMI more fre-
quently underwent treatment of multiple lesions, bifur-
cation or restenotic lesions, received longer stents, and 
had lower post-PCI TIMI flow (Table 2). Multivariable 
predictors of PMI included treatment of bifurcation 
lesion, higher baseline hs-cTnT, lower glomerular fil-
tration rate, and greater total stented length (Table 3) 
(univariable predictors are detailed in Table II in the 
Data Supplement).
PMI and 1-Year Mortality
A total of 220 patients (2.7%) died within 1 year, 
including 182 (2.2%) cardiac deaths. The rate of major 
adverse cardiac events was 4.29%. Mortality was higher 
(6.4%) in patients without serial hs-cTnT measurements 
(P<0.001). Patients with compared with those without 
PMI had a higher risk of all-cause death (HR 5.68, 95% 
CI 3.51–9.20) and cardiac death (HR 6.12, 95% CI 3.67–
10.23), also in landmark analyses between 7 days and 
1 year (Table 4). In multivariable analyses, PMI remained 
a significant predictor of 1-year mortality (adjusted HR 
4.10, 95% CI 2.51–6.68 for death; adjusted HR 4.21, 
95% CI 2.50–7.11 for cardiac death; P<0.001 for both; 
Table 5; Table III in the Data Supplement). These results 
held true in a multivariable model that did not include 
baseline hs-cTnT (Table IV in the Data Supplement). 
Cumulative event curves in patients with or without PMI 
are shown in Figure  2; results including also patients 
without serial hs-cTnT measurements are summarized 
in Figure II in the Data Supplement. Kaplan-Meier curves 
for patients stratified by increments of postprocedural 
Figure 1. Distribution of preprocedural and postprocedural troponin.  
A, Distribution of postprocedural high-sensitivity cardiac troponin T (hs-cTnT) in all patients (n=8 140). Postprocedural values shown are baseline-adjusted accord-
ing to the Society for Cardiovascular Angiography and Interventions (SCAI) algorithm, ie, peak postprocedural in patients with nonelevated preprocedural levels 
(≤1× upper reference limit [URL]) and difference (peak postprocedural minus preprocedural hs-cTnT) in patients with elevated (>1× URL) preprocedural levels. B, 
Dot plot of postprocedural hs-cTnT levels in patients with SCAI-defined periprocedural myocardial infarction (PMI; n=140). Bars indicate median level with inter-
quartile range. C, Distribution of preprocedural hs-cTnT in patients with SCAI-defined PMI (n=140).
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hs-cTnT are shown in Figure  3, indicating a marked 
increase in the risk of mortality at levels above the SCAI 
cutoff value (>70× URL).
One-year mortality was higher in patients with ele-
vated (>1× URL) versus those with nonelevated (≤1× 
URL) baseline troponin (5.47% versus 0.89%, respec-
tively; P<0.001). In a sensitivity analysis including only 
patients with nonelevated baseline troponin (n=4923), 
PMI was associated with a significantly higher rate of 
cardiac, but not all-cause mortality (Tables V and VI in 
the Data Supplement).
Optimal Predictive Threshold of Troponin
According to ROC analysis, a baseline-adjusted postpro-
cedural hs-cTnT >10× URL was identified as the cutoff 
value with the best combination of sensitivity and speci-
ficity for prediction of all-cause death within 1 year. The 
optimal (10× URL) threshold, compared with the SCAI 
threshold (70× URL), had lower specificity (85.7% ver-
sus 98.4%) but higher sensitivity (25.4% versus 8.2%; 
Figure 4), and greater areas under the curve in ROC anal-
ysis (0.60 versus 0.56; P=0.04) for prediction of 1-year 
mortality. The positive predictive value for the optimal 
threshold versus the SCAI threshold was 4.7% versus 
12.9%, and the negative predictive value was 9.8% ver-
sus 9.7%, respectively. Patients with hs-TnT >10× URL 
(n=1185; 14.6%) had a higher risk of 1-year mortal-
ity (adjusted HR 1.74, 95% CI 1.28–2.36) and cardiac 
mortality (adjusted HR 1.87, 95% CI 1.34–2.61) in mul-
tivariable analyses (Figure III in the Data Supplement). 
Compared with patients with postprocedural hs-cTnT 
<10× URL (ie, without PMI according to the optimal cut 
Table 1. Baseline Patient Characteristics
Patient Characteristic
No PMI 
(n=8000)
PMI  
(n=140) P Value
Age, y 70.5 (62.9; 76.7) 71.6 (64.2; 79.9) 0.09
Women 1880 (23.5) 42 (30.0) 0.09
BMI, kg/m2 27.2 (24.7; 30.1) 25.6 (23.5; 29.4) 0.001
Diabetes mellitus 2406 (30.1) 35 (25.0) 0.23
  Insulin-dependent 
diabetes
789 (9.9) 13 (9.3) 0.59
Arterial hypertension 6042 (75.6) 103 (73.6) 0.55
Smoking 1247 (15.6) 25 (17.9) 0.48
Hypercholesterolemia 6279 (78.6) 100 (71.4) 0.048
GFR, mL/min 83.7±34.4 71.7±33.9 <0.001
Renal dysfunction 
(GFR<60 mL/min)
2024 (25.6) 58 (41.7) <0.001
LVEF (%)* 55.7±11.6 53.0±14.0 0.02
History of myocardial 
infarction
2281 (28.5) 39 (27.9) 0.92
History of CABG 1083 (13.54) 19 (13.6) 1.00
Preprocedural hs-cTnT, 
ng/L
10 (10; 20) 12 (10; 41) 0.004
Preprocedural hs-cTnT 
>1× URL, n (%)
3148 (39.35) 69 (49.29) 0.02
Values are mean±SD, median (25th to 75th percentile), or n (%). BMI indicates 
body mass index; CABG, coronary artery bypass graft; GFR, glomerular filtration 
rate; hs-cTnT, high-sensitivity cardiac troponin T;  LVEF, left ventricular ejection 
fraction; PMI, periprocedural myocardial infarction (according to the troponin-
based Society for Cardiovascular Angiography and Interventions [SCAI] definition); 
and URL, upper reference limit.
*Information available in 5979 patients without PMI and 99 patients with 
PMI.
Table 2. Procedural Characteristics
Variable
No PMI
 (n=8000)
PMI
 (n=140) P Value
Patient-level characteristics
  Multivessel disease 5523 (69.0) 98 (70.0) 0.85
  No. of lesions per patient 1.00  
(1.00; 2.00)
2.00  
(1.00; 3.00)
<0.001
  >1 lesions treated 3526 (44.1) 83 (59.3) <0.001
  Bifurcation treatment (at 
least 1 lesion)
2441 (30.6) 59 (42.1) 0.004
  No. of vessels treated
   1 6247 (78.1) 92 (65.7) 0.001
   2 1555 (19.4) 37 (26.4) 0.04
   ≥3 198 (2.5) 11 (7.9) 0.001
  Restenotic lesion treatment 
(at least 1 lesion)
1004 (12.5) 9 (6.4) 0.03
  Balloon diameter (mm, 
max over lesions)
3.32±0.62 3.39±0.68 0.2
Lesion-level characteristics
  Number of lesions 13 132 283  
  Intervened vessel   <0.001
   Left main coronary artery 459 (3.5) 17 (6.0)  
   Left anterior descending 5529 (42.1) 128 (45.2)  
   Left circumflex 3090 (23.5) 71 (25.1)  
   Right coronary artery 3742 (28.5) 56 (19.8)  
   Bypass graft 311 (2.4) 11 (3.9)  
  Stent type per lesion   0.49
   Balloon angioplasty 334 (2.5) 9 (3.2)  
   BMS 277 (2.1) 5 (1.8)  
   BVS 405 (3.1) 4 (1.4)  
   DES 12 110 (92.2) 265 (93.6)  
  Chronic total occlusion 693 (5.3) 10 (3.5) 0.19
  TIMI flow post-PCI   <0.001
   0 24 (0.2) 5 (1.8)  
   1 21 (0.2) 3 (1.1)  
   2 163 (1.2) 13 (4.6)  
   3 12 794 (98.4) 260 (92.5)  
  Lesion length, mm 16.93±10.53 19.36±11.09 0.02
  Total stented length, mm 26.25±13.80 30.83±15.02 <0.001
Values are mean±SD, median (25th to 75th percentile), or n (%). BMS 
indicates bare-metal stent; BVS, bioresorbable vascular scaffold; DES, drug-
eluting stent; and PCI, percutaneous coronary intervention.
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point), the risk of 1-year mortality was higher in those 
with postprocedural hs-cTnT between 10× and 70× URL 
(HR 1.58, 95% CI 1.11–2.25; P=0.011) or >70× (HR 
6.10, 95% CI 3.75–9.93; P<0.001; Figure IV in the Data 
Supplement). An ancillary analysis based on the meth-
odology described by Contal and O’Quigley14 identified 
a similar hs-cTnT level (8× URL) as the optimal cutoff 
value for prediction of 1-year mortality.
Sensitivity Analysis: PMI and Mortality 
in Patients Treated for Chronic Total 
Occlusions
A total of 639 patients were treated for at least 1 chronic 
total occlusion (CTO). The incidence of PMI was 1.56% 
(n=10) according to the SCAI cutoff of hs-cTnT versus 
17.37% (n=111) according to the optimal cutoff (>10× 
URL). There were 9 fatal events in this subgroup; 1-year 
mortality was higher in patients with versus without PMI 
according to the SCAI definition (10% versus 1.27%, 
respectively; P=0.04) but not according to the optimal 
cutoff of hs-cTnT (2.70% versus 1.15% respectively; 
P=0.21; Tables VII and VIII in the Data Supplement).
Troponin Versus CK-MB for Prediction of 
Mortality
CK-MB measurements were available in 7732 patients 
(95% of all patients). Elevation of CK-MB above the 
respective SCAI sthreshold (>10× URL) was observed in 96 
patients (1.24%). Patients with versus without CK-MB-
defined PMI had a higher risk of mortality (adjusted HR 
3.30, 95% CI 1.69–6.46) and cardiac mortality (adjusted 
HR 3.06, 95% CI 1.43–6.54). The c statistic from the 
models including the hs-cTnT-based SCAI definition 
(>70× URL) versus the CK-MB-based SCAI definition of 
PMI (>10× URL) did not differ significantly (P=0.28).
DISCUSSION
The main findings of this study can be summarized 
as follows. First, in a large, contemporary cohort of 
patients undergoing elective PCI by current standards, 
a small proportion (1.7%) of patients fulfilled the SCAI 
definition of PMI based on hs-cTnT. Second, SCAI-
defined PMI emerged as an independent predictor of 
1-year mortality, associated with 4-fold higher risk in 
multivariable analyses. Third, when accounting for the 
combination of sensitivity and specificity, a substantially 
lower cutoff value of hs-cTnT (10× URL) performed 
better than the SCAI threshold; this was because of 
relatively higher sensitivity that outweighed the lower 
specificity of the 10× URL threshold compared with the 
SCAI-defined (70× URL) troponin cutoff. Overall, PMI 
defined by either of these 2 troponin cutoffs (with-
out ancillary clinical criteria) was a weak predictor of 
1-year mortality because of a high rate of false-negative 
results. Fourth, the troponin-based and CK-MB-based 
definitions of PMI according to SCAI had comparable 
value for prediction of 1-year mortality.
PMI according to the troponin cutoff proposed by 
SCAI was observed in 1.7% patients in this analysis. 
Previous studies found a higher incidence of PMI, up to 
5.5% using the CK-MB-based SCAI definition8,9 or up to 
13.3% using the second and third Universal Definition 
of MI (ie, based on lower biomarker thresholds and 
ancillary criteria of myocardial ischemia).16,17 These find-
ings indicate marked heterogeneity in the diagnosis of 
PCI-related MI, depending on the biomarker used and 
Table 3. Multivariable Predictors of SCAI-Defined Periprocedural 
Myocardial Infarction
Variable
Odds Ratio  
(95% CI) P Value
Treatment of bifurcation lesion 1.49 (1.06, 2.11) 0.02
Preprocedural hs-cTnT, ng/L 1.43 (1.16, 1.78) 0.001
Total stented length, per 10 mm 1.32 (1.22, 1.44) <0.001
Glomerular filtration rate, per 20 mL/min 0.81 (0.72, 0.92) 0.001
SCAI indicates Society for Cardiovascular Angiography and Interventions.
Table 4. Clinical Outcomes Within 1 Year in Patients With Versus Without SCAI-Defined PMI
Outcome
All patients
 n=8140
No PMI
 n=8000
PMI
 n=140 HR (95% CI) P Value
Up to 1 y
  Death 220 (2.70%) 202 (2.53%) 18 (12.86%) 5.68 (3.51–9.20) <0.001
  Cardiac death 182 (2.24%) 166 (2.08%) 16 (11.43%) 6.12 (3.67–10.23) <0.001
  MACE 349 (4.29%) (3.26%) (62.86%) 39.24 (30.70–50.15) <0.001
7 days to 1 y
  Death 191/7580 (2.52%) 181/7454 (2.43%) 10/126 (7.94%) 3.58 (1.90–6.77) <0.001
  Cardiac death 155/7580 (2.04%) 147/7454 (1.97%) 8/126 (6.35%) 3.53 (1.73–7.19) 0.001
  MACE 204/7467 (2.73%) 194/7409 (2.62%) 10/58 (17.24%) 8.23 (4.36–15.53) <0.001
Depicted are first events (% from Kaplan-Meier estimate), hazard ratios (HRs; with 95% CI) from Cox’s regression. MACE indicates major 
adverse cardiac events (defined as the composite of cardiac death or myocardial infarction); PMI, periprocedural myocardial infarction; and 
SCAI, Society for Cardiovascular Angiography and Interventions.
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cutoff values applied, as well as the presence or absence 
of clinical signs or symptoms across various definitions.
The magnitude of clinically relevant myocardial 
injury after PCI has remained controversial. It has been 
postulated that over-diagnosis of PMI (on the basis 
of minor biomarker elevations) may lead to needless 
additional testing, prolongation of hospitalization, 
and increased treatment cost, whereas identification 
of a PMI large enough to affect prognosis might ben-
efit these patients by prompting closer postprocedural 
surveillance or more intensive secondary-prevention 
treatment.18 The SCAI expert consensus document 
advocated CK-MB as the preferred biomarker for diag-
nosis of PMI; the respective threshold was based on 
studies linking marked CK-MB elevation to subsequent 
adverse events.7,19 This CK-MB threshold has been 
validated in subsequent investigations as a predictor 
of post-PCI outcomes.8,9 In contrast, the cTn cutoff for 
diagnosis of PMI in the SCAI document was largely 
derived from indirect evidence of bioequivalence of the 
2 biomarkers, based on magnetic resonance imaging 
studies.20 Against this background, the present study 
focused on troponin—a biomarker that has progres-
sively replaced CK-MB as the gold-standard biomarker 
of myocardial injury. Our observations are substanti-
ated further by using a highly sensitive troponin assay 
that is capable of detecting with high precision minor 
cTn elevations.21
This study confirms that PMI based on the SCAI tro-
ponin cutoff independently predicted 1-year mortal-
ity. However, the SCAI threshold of clinically relevant 
Table 5. Multivariable Predictors of 1-Year Mortality
Variable
Hazard Ratio  
(95% CI) P Value
Mortality
  SCAI-defined PMI (based on hs-cTnT) 4.10 (2.51, 6.68) <0.001
  Preprocedural hs-cTnT 1.33 (1.15, 1.54) <0.001
  Age 1.05 (1.04, 1.08) <0.001
  Diabetes mellitus 1.49 (1.12, 1.99) 0.006
  Arterial hypertension 0.50 (0.37, 0.66) <0.001
  Glomerular filtration rate 0.98 (0.97, 0.98) <0.001
Cardiac mortality
  SCAI-defined PMI (based on hs-cTnT) 4.21 (2.50, 7.11) <0.001
  Preprocedural hs-cTnT 1.33 (1.15, 1.55) <0.001
  Age 1.05 (1.03, 1.07) <0.001
  Diabetes mellitus 1.42 (1.03, 1.95) 0.033
  Arterial hypertension 0.41 (0.30, 0.56) <0.001
  Glomerular filtration rate 0.98 (0.97, 0.98) <0.001
hs-cTnT indicates high-sensitivity cardiac troponin T;  PMI, periprocedural 
myocardial infarction; and SCAI, Society for Cardiovascular Angiography and 
Interventions.
Figure 2. Kaplan-Meier curves for all-cause mortality and cardiac mortality in patients with or without Society for Cardiovascular Angiography and 
Interventions (SCAI)-defined periprocedural myocardial infarction.  
A and B, Analyses up to 1 y. C and D, Respective landmark analyses at 7 d.
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troponin elevation did not emerge as the optimal thresh-
old in our analysis addressing 2 partly competing mea-
sures of the biomarker’s discriminating ability, that is, 
sensitivity (the probability of detecting at-risk patients, 
thus minimizing false negative results) and specificity 
(minimizing false positive outcomes). As with all bio-
markers, the high troponin cutoff proposed by SCAI 
was highly specific (higher positive predictive value) 
but had low sensitivity in this study and identified only 
8% of patients who died within 1 year. Accordingly, 
the presence, rather than absence of SCAI-defined PMI 
appears to be prognostically more relevant, as patients 
with PMI had 4-fold higher likelihood to die within 1 
year. Based on ROC analysis (notably, also supported 
by an ancillary statistical approach14), optimal combi-
nation of sensitivity and specificity was observed at 
a lower hs-cTnT cutoff (>10× URL)—a criterion met 
9× more commonly than the SCAI cutoff. This find-
ing is more along the lines of an earlier investigation 
by Herrmann et al,22 which identified a prognostically 
optimal threshold of 25× URL for post-PCI cTn rise 
(ie, a value in between the Universal Definition of MI6 
and SCAI5 criteria). The latter study was limited by a 
small number of events (n=20) confined to a 3-month 
follow-up period; it included patients with stable CAD 
as well as recent acute coronary syndromes; and used 
earlier, less sensitive troponin assays.22 A recent study 
by Zeitouni et al17 in 1390 elective PCI patients found a 
higher rate of 1-year cardiovascular events in patients 
with PMI according to the Universal Definition of MI 
criteria, that is, hs-cTnT rise above 5× URL and addi-
tional clinical evidence of myocardial ischemia.
Taken together, while post-PCI troponin eleva-
tion above the SCAI threshold of cTn was associated 
with adverse prognosis, a lower magnitude of hs-cTnT 
elevation (10× URL) emerged as an overall more accu-
rate prognostic marker that led to a better trade-off 
in terms of ruling-in versus ruling-out of patients who 
subsequently died. In view of highly heterogeneous 
existing definitions of PMI,5,6 a widely accepted defi-
nition would facilitate identification of patients with 
clinically significant myocardial damage and enable 
consistency across clinical studies. Against this back-
ground, our findings indicate that coupling diagnosis 
of PMI with subsequent prognosis18 (a concept intro-
duced in the SCAI document5) may be achieved at a 
lower magnitude of postprocedural troponin elevation 
than proposed in the SCAI definition. Collectively, it 
should be noted that, according to ROC analysis: (1) 
the optimal cutoff only marginally outperformed the 
SCAI cutoff value of troponin; and (2) cTnT elevation as 
a standalone criterion of PMI (ie, without ancillary signs 
of ischemia) emerged as a particularly weak predictor 
of 1-year mortality at any cutoff level, as suggested by 
the low area under the curve values.
Myocardial injury occurs frequently in the complex 
setting of PCI in CTO lesions. We found that troponin 
elevation above the SCAI cutoff, but not above the 
cutoff >10× URL, was associated with higher 1-year 
mortality. These observations require cautious inter-
pretation, considering the small numbers of events in 
this subgroups analysis. Our findings are along the lines 
of a dedicated analysis by Lee et al8 showing that only 
marked elevation of CK-MB (as in the SCAI definition) 
predicted mortality in 1058 patients with CTO. Our 
results also align with a study by Dautov et al23 indicat-
ing that modest troponin elevation (>5× URL) did not 
predict major adverse cardiac events within a 1.2-year 
follow-up in 469 patients treated for CTO.
Previous studies have indicated greater prognostic 
value of preprocedural compared with postprocedural 
biomarker elevation.24 In this analysis, we found that 
SCAI-defined PMI was not associated with significant 
increase in all-cause mortality in the context of nonel-
evated preprocedural troponin levels. Ndrepepa et al25 
recently showed that hs-cTnT measured post-PCI does 
not offer incremental prognostic information beyond 
that provided by the baseline level for prediction of 
3-year mortality. Against this background, it is impor-
tant to note that that (1) the SCAI definition of PMI, 
Figure 3. Kaplan-Meier curves for 1-y all-cause mortality and cardiac 
mortality in patients stratified by increments of postprocedural hs-
cTnT levels (multiples of the upper reference limit [URL]).  
A and B, Postprocedural values shown are baseline-adjusted according to the 
Society for Cardiovascular Angiography and Interventions (SCAI) algorithm, ie, 
peak postprocedural in patients with nonelevated preprocedural levels (≤1× 
URL) and difference (peak postprocedural minus preprocedural hs-cTnT) in 
patients with elevated (>1× URL) preprocedural levels.
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applied in the present study, accounts for both pre- and 
postprocedural cTn levels5; and (2) baseline levels were 
elevated in 40% of all patients and in half of patients 
with PMI. Collectively, because of conclusive previous 
evidence,25 the primary aim of this analysis was not to 
compare the relative prognostic impact of baseline ver-
sus post-PCI troponin levels; rather, we tested the prog-
nostic performance of a PMI definition5 incorporating 
both pre- and post-PCI measurements.
This study is the first to directly compare the hs-
troponin-based versus CK-MB-based definitions of 
PMI with respect to subsequent outcomes. We found 
that the 2 biomarkers, at the cutoff values proposed 
by SCAI, confer comparable prognostic information 
about 1-year mortality. In view of the prevailing use of 
troponins over CK-MB in clinical practice,21 this finding 
supports the bioequivalence assumptions in the SCAI 
consensus document.5 While the CK-MB-based PMI 
definition has been assessed after PCI for CTOs8 or mul-
tivessel CAD9 (ie, clinical conditions which per se may 
affect the magnitude and clinical sequelae of biomarker 
release), the present study analyzed a broadly inclusive 
population undergoing interventions across a wide 
spectrum of CAD, ranging from simple, single lesions 
to complex, multivessel treatment.
This observational study has several limitations. First, 
while clinical outcomes were collected prospectively, this 
is a retrospective analysis reflecting the experience of 2 
large-volume centers. Second, clinical or ECG signs of 
myocardial ischemia were not consistently available in 
this pooled dataset; therefore, similar to previous stud-
ies assessing the prognostic relevance of cardiac bio-
marker elevation,9,19,22 we explored the SCAI definition 
of PMI that only considers biomarker elevations with-
out ancillary criteria. Third, this study cannot elucidate 
mechanisms responsible for cTn elevation and for its 
association with subsequent outcomes, in particular 
delayed mortality (ie, beyond the first days following 
the procedure). Fourth, although we performed exten-
sive adjustments, unmeasured confounders affecting 
cTn elevation as well as clinical outcomes cannot be 
excluded. The optimal prognostic cut point for troponin 
identified in this analysis should be further validated in 
future studies. Measurements of cTn were performed 
in accordance with common clinical practice in our cen-
ters and the exact timing of blood sampling following 
PCI was not recorded; similar to previous reports,8,9,25 
we cannot exclude the possibility that peak postpro-
cedural values may have been missed in a number of 
patients. Finally, because this cohort included only few 
Figure 4. Incidence and prognostic relevance of periprocedural myocardial infarction (PMI) according to the Society for Cardiovascular Angiography 
and Interventions (SCAI) versus the optimal prognostic threshold.  
A, Venn diagram showing the incidence of periprocedural myocardial infarction (PMI) according to the Society for Cardiovascular Angiography and Interventions 
(SCAI) threshold (hs-cTnT >70× upper reference limit [URL]; 1.7%) versus the optimal prognostic threshold (>10× URL; 14.6%). B, Adjusted hazard ratio for all-
cause mortality in patients with PMI according to the SCAI threshold vs the optimal threshold. C, ROC analysis of hs-cTnT elevation for prediction of 1-y mortality; 
the SCAI threshold (red) and the optimal threshold (blue) are indicated on the curve. Specificity is higher for the SCAI threshold (D), whereas sensitivity is higher for 
the optimal threshold of hs-cTnT (E).
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patients without serial troponin measurements who had 
a less favorable risk-factor profile (Table I in the Data 
Supplement) and higher 1-year mortality, this study can-
not address the question whether measuring myocardial 
biomarkers routinely offers incremental prognostic value 
compared with a more conservative approach of assess-
ing PMI only if deemed clinically indicated.
CONCLUSIONS
In a large, contemporary population of patients undergo-
ing elective PCI, SCAI-defined PMI was an independent 
predictor of 1-year mortality. The SCAI cutoff value of hs-
cTnT (>70× URL) was associated with 4-fold increase in 
mortality risk and emerged as a highly specific but insen-
sitive prognostic marker. If optimal trade-off between 
sensitivity and specificity for prediction of mid-term sur-
vival is sought, then a substantially lower, less restrictive 
threshold of hs-cTnT (10× URL) should be considered.
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